Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares traded -8.11% lower at $1.02 on Wall Street last session.
In accordance with the data, 6 analysts cover Praxis Precision Medicines Inc. (NASDAQ:PRAX). The consensus rating among analysts is ‘Overweight’. PRAX stock price is now -70.34% away from the 50-day moving average and -68.40% away from the 200-day moving average. The market capitalization of the company currently stands at $156.53M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 3 analysts and a buy by 3.
With the price target maintained at $4, Wedbush recently Downgraded its rating from Outperform to Neutral for Praxis Precision Medicines Inc. (NASDAQ: PRAX). On December 16, 2021, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $48, while ‘BofA Securities’ rates the stock as ‘Buy’.
In other news, Mastrocola Lauren, Principal Accounting Officer bought 3,000 shares of the company’s stock on Jun 16. The stock was bought for $5,775 at an average price of $1.93. Upon completion of the transaction, the Principal Accounting Officer now directly owns 31,391 shares in the company, valued at $32018.82. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 13, General Counsel and Secretary Nemiroff Alex bought 7,500 shares of the business’s stock. A total of $12,225 was incurred on buying the stock at an average price of $1.63. This leaves the insider owning 39,347 shares of the company worth $40133.94. Insiders disposed of 6,013 shares of company stock worth roughly $6133.26 over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRAX stock. A new stake in Praxis Precision Medicines Inc. shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $2,032,000. OCTAGON CAPITAL ADVISORS LP invested $888,000 in shares of PRAX during the first quarter. In the first quarter, ALLY BRIDGE GROUP (NY) LLC acquired a new stake in Praxis Precision Medicines Inc. valued at approximately $700,000. BIOIMPACT CAPITAL LLC acquired a new stake in PRAX for approximately $677,000. CIBC ASSET MANAGEMENT INC purchased a new stake in PRAX valued at around $421,000 in the second quarter. In total, there are 158 active investors with 90.30% ownership of the company’s stock.
Praxis Precision Medicines Inc. (NASDAQ: PRAX) opened at $1.0700 on Tuesday. During the past 12 months, Praxis Precision Medicines Inc. has had a low of $0.98 and a high of $13.86. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.20, and a quick ratio of 3.20. The fifty day moving average price for PRAX is $3.4388 and a two-hundred day moving average price translates $3.2282 for the stock.
The latest earnings results from Praxis Precision Medicines Inc. (NASDAQ: PRAX) was released for Dec, 2022.
Praxis Precision Medicines Inc.(PRAX) Company Profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson’s disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
